Markus Gerhard is an expert in Gastroenterology at Technical University of Munich (Germany). Markus Gerhard has authored 165 publications, the most recent in 2026, and is an investigator in 1 clinical trial, 1 of them ongoing. SLR score: 575 (community average: 125). How the SLR is computed.

LeadR Profile

Markus Gerhard Technical University of Munich Germany
575 ScienceLeadR Reputation 575
Network Map

Gastroenterology

Subspecialties: Infectiology - Oncology - Transplantation

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1997 - 2026

Source: PubMed

Technical University of Munich

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 165

Citations

Citations: 8 938 1st author: 10 Last author: 41 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Biomaterial-driven remove-remodel-repair (3R) strategy for full-cycle gastric cancer management: bibliometric mapping, preclinical evidence, and a translational roadmap.
PMID 42877086 — neoplasms, rehabilitation, biocompatible materials, therapeutics, tissues, stomach neoplasms
Nanoscale Adv20260
Helicobacter pylori infection, treatment and colorectal cancer risk by genetic predisposition: evidence from two randomised trials.
PMID 42379837 — helicobacter pylori, genetic predisposition to disease, helicobacter, neoplasms, therapeutics, colorectal neoplasms, virulence, infections, virulence factors
Gut20260
Metronidazole and ether derivatives target Helicobacter pylori via simultaneous stress induction and inhibition.
PMID 41851492 — ether, helicobacter pylori, metronidazole, pharmaceutical preparations, stress, physiological, helicobacter, therapeutics
Nat Microbiol20260
Helicobacter pylori Screen-and-Treat Programs for Gastric Cancer Prevention - IARC Working Group Report.
PMID 41812202 — helicobacter pylori, helicobacter, neoplasms, stomach neoplasms
N Engl J Med Top journal20262
Impact of Helicobacter pylori on Immune Checkpoint Inhibition in Hepatocellular Carcinoma: A Multicenter Study.
PMID 39970893 — carcinoma, hepatocellular, helicobacter pylori, gastroenterology, helicobacter, sorafenib, therapeutics
Digestion20250

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 1

By status:

Recruiting 1

By type:

Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Helicobacter Pylori Local Prevalence and Antibiotic Resistance
NCT05561504 — bacterial infections, helicobacter pylori, pharmaceutical preparations, helicobacter, neoplasms, prevalence, gastritis, therapeutics, communicable diseases, stomach neoplasms, infections
N/ARecruiting2021

LeadR Networks

Main global connection map